Composition for improving cognition and memory
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8859593-B2
Publication Date
2014-10-14
Expiration Date
Abstract
The invention relates to a pharmacologically active combination, having utility in treating insomnia patients, which comprises: (a) at least one first active ingredient selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists; and (b) at least one second active ingredient selected from nicotine and nicotine receptor agonists; to use of a medicament containing component (a) with or without component (b) for alleviation of at least one adverse effect which occurs in a patient in the course of nicotine replacement therapy, or otherwise, selected from impairment of the quality of sleep, impairment of cognition and impairment of memory, as well as to a kit having utility in treating insomnia patients, which comprises components (a) and (b) in unit dosage form.
Core Innovation
The invention relates to pharmacologically active combinations for treating insomnia and alleviating adverse effects associated with nicotine replacement therapy. It uses a first medicament comprising at least one active ingredient melatonin and a second medicament comprising a second active ingredient selected from nicotine and nicotine receptor agonists, administered during the course of nicotine replacement therapy to address nicotine withdrawal-related adverse effects.
The method is directed to alleviating at least one adverse effect occurring in a patient in need thereof as a result of nicotine withdrawal, with the adverse effect selected from impairment of cognition and impairment of memory. The method comprises administering the melatonin medicament prior to bedtime while the patient is receiving simultaneously the nicotine or nicotine receptor agonist medicament.
The disclosed embodiments also include formulations in which the melatonin is provided in a controlled, sustained or prolonged release formulation. In the further defined embodiment, the nicotine active ingredient is provided in the form of a transdermal patch, and the disclosed approaches further encompass separate or single formulations and different routes of administration for dosage units.
Claims Coverage
The document contains two independent method claims covering a method for alleviating nicotine withdrawal-related adverse effects during nicotine replacement therapy. Across the independent claims, the inventive features focus on the melatonin and nicotine or nicotine receptor agonist combination, timing prior to bedtime, and specific formulation pairings in one claim, with additional delivery-form and dosage-range constraints addressed in dependent claims.
Melatonin administered prior to bedtime with simultaneous nicotine receptor agonist during nicotine replacement therapy
Administering prior to bedtime a first medicament comprising at least one active ingredient melatonin to a patient receiving nicotine replacement therapy, while simultaneously administering a second medicament comprising a second active ingredient selected from nicotine and nicotine receptor agonists, for alleviating at least one adverse effect selected from impairment of cognition and impairment of memory occurring as a result of nicotine withdrawal.
Controlled, sustained or prolonged release melatonin with transdermal patch nicotine during nicotine replacement therapy
Administering prior to bedtime to a patient receiving nicotine replacement therapy a first medicament comprising at least one active ingredient melatonin in a controlled, sustained or prolonged release formulation, together with simultaneously administered second medicament comprising a second active ingredient selected from nicotine and nicotine receptor agonists provided in the form of a transdermal patch, for alleviating at least one adverse effect selected from impairment of cognition and impairment of memory.
Both independent claims define treating nicotine withdrawal-related impairment of cognition and/or memory during nicotine replacement therapy by combining melatonin administered prior to bedtime with simultaneous administration of nicotine or nicotine receptor agonists. One independent claim additionally specifies that melatonin is in a controlled, sustained or prolonged release formulation while nicotine or agonist is provided as a transdermal patch.
Stated Advantages
Alleviating at least one adverse effect selected from impairment of cognition and impairment of memory occurring as a result of nicotine withdrawal during nicotine replacement therapy.
Documented Applications
Treating a patient during nicotine replacement therapy to alleviate adverse effects, including impairment of cognition and/or impairment of memory, occurring as a result of nicotine withdrawal.
Treating impairment of cognition and impairment of memory by administering melatonin prior to bedtime while the patient simultaneously receives nicotine or a nicotine receptor agonist during nicotine replacement therapy.
Interested in licensing this patent?